Life Sciences

  • April 17, 2026

    Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says

    The Fourth Circuit ruled Friday that a surgery patient's missed expert disclosure deadline rightfully ended his case seeking to hold Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC liable for allegedly faulty staples used in his procedure.

  • April 17, 2026

    Kenvue Says Shea & Cocoa Butter Oil Is Accurately Labeled

    Kenvue urged a New Jersey federal court to nix a proposed class action alleging its shea and cocoa butter oil is deceptively advertised, as it's primarily made with a petroleum byproduct, arguing Thursday the front label truthfully identifies it as an oil enriched with shea and cocoa butter. 

  • April 17, 2026

    3 Key Questions On Trump's Pharma Tariffs

    President Donald Trump recently announced 100% tariffs on certain imported pharmaceutical products, with opportunities for drug companies to lower their tariff rates to zero, but questions remain about the requirements for preferential treatment and abilities to administer the regime. Here, Law360 examines three open questions surrounding pharmaceutical tariffs' implementation.

  • April 17, 2026

    AI Health Co. Illegally Shared Genetic Data, Patients Say

    A healthcare company powered by artificial intelligence violated Illinois' genetic privacy law and other consumer protection laws by compelling a genetic testing business it acquired to disclose patients' genetic information, which it then shared through data agreements with pharmaceutical giants such as Eli Lilly and AbbVie, a lawsuit in Illinois federal court says.

  • April 17, 2026

    Judge Says Biotech Co. Can't Wipe Cancer Data, For Now

    A Texas state judge signed a temporary restraining order on Friday that stops Bellicum Pharmaceuticals Inc. and the consulting firm helping it oversee its dissolution from deleting cell therapy data that the Houston-based MD Anderson Cancer Center says belongs to it.

  • April 17, 2026

    Life Sciences Firm Says Ex-VP Took Trade Secrets To Rival

    A Massachusetts life sciences startup says a former vice president who left the company last fall, purportedly to care for his ill wife, instead took trade secrets with him to a new job at a California rival.

  • April 17, 2026

    Aramark Joins NJ Insulin Pricing Suits Against PBMs

    Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.

  • April 17, 2026

    Polsinelli Sent Bogus Infringement Letters, Suits Say

    National law firm Polsinelli PC was accused of sending letters to two medical device companies with meritless claims of patent infringement, the companies claimed in a pair of malpractice suits.

  • April 17, 2026

    Latham Leads Kailera's $625M IPO In Obesity Drug Push

    Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years.

  • April 17, 2026

    Doc Says Texas Man Can't Sue Over Mailed Abortion Pills

    A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions. 

  • April 17, 2026

    Fed. Circ. Reverses $18M Penile Implant Trade Secret Win

    In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.

  • April 16, 2026

    Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief

    President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.

  • April 16, 2026

    Wis. Supreme Court Upholds Pabst Asbestos Verdict

    The Wisconsin Supreme Court upheld a verdict in favor of the estate of a steamfitter exposed to asbestos through his work at a Pabst Brewing Co. brewery, saying Wednesday that the company still owed a duty of care to employees of independent contractors, but capped punitive damages to about $4.65 million.

  • April 16, 2026

    Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win

    The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.

  • April 16, 2026

    IV Device Redesign Not Enough To Lift Ban, CBP Says

    A U.S. medical device company's redesigned products used for intravenous drips are still barred from importation into the country, U.S. Customs and Border Protection said in an order released Thursday, with the agency unconvinced the new versions aren't still patent-infringing.

  • April 16, 2026

    USPTO Ends COVID Patent Appeals Program

    The U.S. Patent and Trademark Office has decided to end a program launched five years ago that aimed to prioritize and fast-track ex parte appeals of rejections on patent applications for inventions related to combating COVID-19.

  • April 16, 2026

    Katten Partner Rejoins Epstein Becker In DC For 3rd Time

    Epstein Becker Green LLP has rehired, for the third time, a healthcare transactional attorney who focuses his practice on guiding hospital systems, private equity-backed entities and professional practices on transactional matters and regulatory compliance.

  • April 15, 2026

    Consumer Cases Drive Class Action Spike, Report Says

    Federal class action filings spiked in 2025 after nearly a decade of relative stability, fueled by a surge in consumer protection lawsuits tied to data breaches, digital commerce and online accessibility claims, according to a new report from Lex Machina.

  • April 15, 2026

    Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit

    There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.

  • April 15, 2026

    Drugmaker Aquestive's Brass Sued Over FDA Setback

    Executives and directors of pharmaceutical company Aquestive Therapeutics Inc. were hit with a shareholder's derivative suit Wednesday accusing them of ignoring deficiencies in a research study for Aquestive's allergic reaction treatment, which eventually prompted the U.S. Food and Drug Administration to reject the company's new drug application.

  • April 15, 2026

    Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini

    A lead attorney on the U.S. Department of Justice Antitrust Division's monopolization cases against Google LLC who left the agency last week joined Wilson Sonsini Goodrich & Rosati PC in Washington, D.C., on Wednesday as a partner.

  • April 15, 2026

    Squires Passes On 10 Patent Challenges, Takes On 2 Others

    The newest bulk order from U.S. Patent and Trademark Office Director John Squires has rejected 10 petitions for America Invents Act patent reviews while granting a couple others, including a Google challenge to a patent owned by Headwater Research LLC.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 15, 2026

    Willkie Adds O'Melveny Litigator To Los Angeles Office

    Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.

  • April 15, 2026

    Biopharma Co. Says Ex-Worker Used Files To Build AI Rival

    A biopharmaceutical consulting firm's ex-contractor illegally downloaded thousands of proprietary internal files and emails that he then used to launch a rival company powered by artificial intelligence, the firm claimed in a lawsuit, alleging that the former contractor violated federal trade secrets law.

Expert Analysis

  • 4 Quick Emotional Resets For Lawyers With Conflict Fatigue

    Author Photo

    Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

  • Navigating Trade Secret Exceptions In Noncompete Bans

    Author Photo

    Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.